Agilent Technologies Inc Stock Price, News & Analysis

Agilent Technologies (NYSE: A) has received FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test for colorectal cancer. The test identifies mismatch repair deficient (dMMR) colorectal cancer patients eligible for treatment with Bristol Myers Squibb's Opdivo alone or in combination with Yervoy.

The panel is the only FDA-approved companion diagnostic IHC panel for this specific purpose and is exclusively designed for use with Agilent's Dako Omnis automated staining solution. The test detects loss of function in four key MMR proteins (MLH1, PMS2, MSH2, and MSH6) in colorectal cancer tissue, helping identify patients who may respond better to immunotherapy.

TORM plc (NASDAQ: TRMD) reported Q2 2025 financial results with TCE earnings of USD 208.2 million and a net profit of USD 58.7 million, showing a year-over-year decline from Q2 2024's exceptional performance. The company achieved average TCE rates of USD 26,672 per day across its fleet.

TORM declared a quarterly dividend of USD 0.40 per share, representing a 67% payout ratio. The company has also secured financing commitments of up to USD 857 million to refinance existing loans and lease agreements.

Following strong performance and positive outlook, TORM has raised its full-year 2025 guidance, projecting TCE earnings of USD 800-950 million and EBITDA of USD 475-625 million.

Agilent Technologies (NYSE:A) and Georgia Tech have announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering. The center will be led by renowned environmental scientist Professor Shane Snyder from Georgia Tech's School of Civil and Environmental Engineering.

The CoE will focus on advancing research in environmental sustainability, water recycling, and biologics. Key research areas include developing novel water recycling technologies, waste material upcycling, and cell-based analysis of environmental mixtures. This marks Agilent's third CoE in the U.S. and will be uniquely positioned to evaluate environmental contaminants and toxicity.

Agilent Technologies (NYSE: A) has launched three new models in its Dako Omnis instrument family to address diverse pathology laboratory needs. The new lineup includes the Dako Omnis 110 for low-medium volume labs (110 IHC slides/day), Dako Omnis 165 for medium-high volume labs (165 IHC slides/day), and Dako Omnis 165 Duo for simultaneous IHC and ISH processing.

The new instruments feature continuous case-based processing, shared reagents, and an integrated direct connection for de-ionized water and non-hazardous waste to improve workflow efficiency. The products will be initially available in the U.S., Europe, and Australia, with debuts planned at the European Congress of Pathology and National Society for Histotechnology events.

Crawford & Company (NYSE: CRD-A and CRD-B) announced an increase in its quarterly dividend. The Board of Directors approved a quarterly dividend of $0.075 per share for both Class A and Class B Common Stock, representing a $0.005 increase from the previous quarter.

The dividend will be paid on August 29, 2025, to shareholders of record as of August 15, 2025.

Agilent Technologies (NYSE: A) has announced it will release its third quarter fiscal 2025 financial results on Wednesday, August 27, 2025, after market close. The company will host a conference call at 1:30 p.m. PDT the same day to discuss the results. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website. A replay of the call will remain available on the website for 90 days.

Agilent Technologies (NYSE: A) announced that Senior Vice President and CFO Bob McMahon will step down effective July 31, as he relocates to the East Coast for family reasons. Rodney Gonsalves, the company's current corporate controller and principal accounting officer, will serve as interim CFO while a global search for McMahon's successor is conducted.

The company also confirmed that its Q3 FY2025 financial results, to be released on August 27, are expected to be within the previously provided guidance range. Agilent maintains confidence in its long-term plans.

Agilent Technologies announced plans to showcase new laboratory equipment at HPLC 2025 in Bruges, Belgium. The company will introduce their new Hybrid Multisampler and LC Single Quadrupole Mass Spectrometers. The InfinityLab Pro iQ Series features enhanced sensitivity for analyzing oligonucleotides, therapeutic peptides, and proteins, with real-time status feedback and mass-based fraction collection capabilities. The eco-friendly system has earned MyGreenLab ACT EcoLabel 2.0 certification. The 1290 Infinity III Hybrid Multisampler offers both traditional flow-through and Feed Injection Mode, reducing sample preparation time and ensuring better peak shapes. Early adopters like Novopor Advanced Science report significant workflow improvements, praising the system's robustness, reproducibility, and user-friendly interface. Agilent will also preview a new fluorescence detector and showcase enhanced serviceable flow cells and expanded Bio Core offerings.

Crawford & Company (NYSE: CRD-A and CRD-B) has appointed Amy Shore as an independent director effective June 6, 2025, expanding their board to ten directors, including three women. Shore brings over 30 years of leadership experience in financial services, most recently serving as chief transformation officer at Nationwide Insurance. In her previous role as chief customer officer, she managed customer strategy for a $60B enterprise serving 14 million customers. Shore holds a bachelor's degree from Bowling Green State University, where she currently serves as board chair, and has completed executive programs at Northwestern's Kellogg School and UC Berkeley. A 2023 finalist for 50/50 Women on Boards' "50 Women to Watch for Boards," Shore's expertise in business transformation, customer experience, and operational excellence is expected to contribute to Crawford's strategic growth.